Naveen Pemmaraju: It’s time to talk about revised endpoints for Myelofibrosis clinical trials

Naveen Pemmaraju shared on X/Twitter:

“It’s time to talk about revised endpoints for Myelofibrosis clinical trials in the new era of novel treatments. We must move beyond/add to spleen-positive symptoms.

We must focus on OS, PFS, EFS, blast percentage, improvement, anaemia improvement, and bridge to alloSCT.”

Read further.
Source: Naveen Pemmaraju/X

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.

His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.

He has been named MDACC’s, Department of Leukemia, Inaugural Director of BPDCN Program, in 2020, which is one of the world’s most active BPDCN research programs.

Dr. Pemmaraju is the recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. He is a well-known social media influencer and advocate.